Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors.

Ezeamuzie, C I

Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors. [electronic resource] - European journal of pharmacology Apr 2001 - 11-8 p. digital

Publication Type: Journal Article

0014-2999

10.1016/s0014-2999(01)00821-4 doi


3',5'-Cyclic-AMP Phosphodiesterases--antagonists & inhibitors
Adenylyl Cyclases--metabolism
Adult
Albuterol--pharmacology
Benzamides--pharmacology
Cell Degranulation--drug effects
Colforsin--pharmacology
Cyclic AMP--metabolism
Cyclic Nucleotide Phosphodiesterases, Type 4
Cyclohexanecarboxylic Acids--pharmacology
Dinoprostone--pharmacology
Dose-Response Relationship, Drug
Enzyme Activation--drug effects
Eosinophil Peroxidase
Eosinophils--drug effects
Histamine--pharmacology
Humans
Nitriles
Peroxidases--drug effects
Phosphodiesterase Inhibitors--pharmacology
Pyridines--pharmacology
Rolipram--pharmacology
Superoxides--metabolism
Theophylline--pharmacology